viewGlaxoSmithKline PLC

GlaxoSmithKline receives HIV treatment knock-back in the USA

Glaxo's specialist HIV drugs division, in which Pfizer and Shionogi have stakes, has been developing the once-a-month injection as an alternative to daily treatments

GlaxoSmithKline PLC -

The US Food and Drug Administration (FDA) has declined to approve an HIV treatment backed by drugs giants GlaxoSmithKline PLC (LON:GSK), Pfizer and Shionogi.

ViiV Healthcare, Glaxo’s specialist HIV drugs division, received what is known as a complete response letter from the FDA regarding its application for the cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.

On the plus side, there were no safety issues flagged by the FDA with the once-a-month injection and there is no change to the safety profile of the products used in clinical trials to date.

The FDA is, however, concerned about chemistry manufacturing and controls.

ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this new drug application.

Shares in Glaxo were down 0.8% at 1,798p in early deals.

Quick facts: GlaxoSmithKline PLC

Price: 1629.8 GBX

Market: LSE
Market Cap: £817.17 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Plenty more deals in the pipeline for Greencoat UK Wind PLC says manager

There are still plenty of opportunities in the acquisition pipeline for onshore UK wind farm operator Greencoat UK Wind PLC (LON:UKW) according to investment manager Stephen Lilley. The fund had a busy 2019, Lilley told Proactive, with £600mln invested and £200mln committed for new projects...

4 hours, 39 minutes ago

2 min read